Ceapro Inc. and NATEX Collaborate on PGX Technology Scale-Up
Wednesday, November 08, 2023
Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) has announced a technical collaboration with NATEX Prozesstechnologie GmbH, a company based in Austria, to accelerate the scale-up of its proprietary PGX Technology for commercial use. Ceapro is a biotechnology company focused on developing active ingredients and disruptive technologies for the healthcare and cosmetic industries. This collaboration leverages Ceapro's expertise in natural ingredient processing and NATEX's knowledge of commercial high-pressure extraction equipment to enable sustainable large-scale production of PGX materials.
This agreement is part of Ceapro's efforts to expedite the time to market for PGX-processed materials. The initial plan for sequential scale-up from 10L to 50L and then 100L has been revised to proceed concurrently. Ceapro's ability to define specifications and test methods for high purity YBG (a component of PGX) has reduced uncertainties, allowing the installation and testing of a 50L plant at Ceapro's existing facility in Edmonton, Canada. Pilot production at this facility benefits from its existing manufacturing site license for natural health products. Space at the University of Alberta, where the original scale-up was planned, is retained for potential future projects.
NATEX's expertise in designing and constructing high-pressure supercritical CO2 processing plants has expedited the construction of a 100L plant in parallel with the 50L plant. The 100L plant is expected to be completed by the third quarter of 2024.
PGX Technology has the potential to revolutionize drug and bioactive delivery, opening the door to innovative nutraceutical and pharmaceutical products. This collaboration offers significant growth opportunities for both Ceapro and NATEX, as it envisions the deployment of multiple commercial plants for various new products.
Ceapro, expressed the company's commitment to a focused timeline for scaling up PGX and credited the collaboration with NATEX for expediting these projects.
NATEX, highlighted how this collaboration aligns with their expertise in supercritical fluid technologies and their mission to introduce new industrial processes for innovative products.
Ceapro, emphasized the importance of the PGX Technology for the company's future and the potential it holds for creating innovative nutraceuticals and pharmaceuticals.
Ceapro's patented PGX Technology is a disruptive supercritical fluid technology with advantages over conventional drying and purification methods. It is particularly well-suited for processing challenging high-molecular-weight, water-soluble biopolymers, creating ultra-light, highly porous polymer structures not achievable with traditional technologies. PGX Technology was developed by Dr. Feral Temelli and Dr. Bernhard Seifried, and Ceapro holds exclusive worldwide rights for its industrial applications.
Source: globenewswire.com
